Preclinical studies have shown sensitivity of immortalized cell lines and KRASG12C patient-derived cells to combined cetuximab and sotorasib (KRAS inhibitor) treatment.81 Patient-derived xenograft models similarly exhibited tumor regression following cetuximab plus sotorasib or adagrasib administration.81,82 Key ongoing trials of adagrasib with cetuximab as combination partner include KRYSTAL-1 and KRYSTAL-10. This evidence concerns the gene KRAS and neoplasm.